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Introduction
Epidemiology
Currently, more than 350 million people are chronically infected
with hepatitis B (HBV)[1]. In recognition of the large global
burden of disease, the World Health Organization established the
Global Hepatitis Programme in 2010 [2].
Prevalence rates are highest in Central and Southeast Asia
including China, central areas of South America and sub-Saharan
Africa, where most transmission is perinatal [1,3]. Approximately
686,000 deaths annually are due to HBV [4]. Hepatitis B causes
over half of all primary liver cancers in Africa, China and Southeast
Asia [5]. The majority of chronic hepatitis B (CHB) cases are
HBeAg-positive, although a growing proportion is
HBeAg-negative, making up 15% of patients in Asia and the
Pacific, and one-third of patients in the Mediterranean [5,6].
Between 5% and 20% of HBV carriers are co-infected with
hepatitis C (HCV)[7], and 10–25% of HIV-positive people are
co-infected with HBV [8]. Co-infection with HCV is associated
with increased risks of liver cirrhosis and hepatocellular carcinoma
(HCC)[7]. Co-infection with HIV leads to higher levels of HBV
viraemia, increased risk of progression from acute to chronic HBV
infection, and higher rates of cirrhosis and HCC [6,8].
Treatment guidelines
Current guidelines outline three different approaches to
treatment: finite-duration treatment with pegylated interferon or
nucleos(t)ide analogue (NA), or long-term treatment with NAs.
Monotherapy with either entecavir (ETV) or tenofovir disoproxil
fumarate (TDF) is recommended as first-line treatment in
international treatment guidelines, including new WHO
guidelines published in March 2015 [6,9–11]. The UK’s National
Institute for Health and Care Excellence (NICE) recommends
initial treatment with peginterferon alpha-2a before offering
entecavir or TDF monotherapy [12]. Both entecavir and TDF are
highly effective and pose high genetic barriers to resistance, with
<1.2% and 0% resistance, respectively, at 5 years [6]. Entecavir
has a low risk of adverse effects [9], while TDF poses some risk
in terms of nephrotoxicity, and decreases in bone mineral density
in HIV-positive patients [6,9] and in selected HBV mono-infected
patients [13]. Entecavir is not recommended in patients
previously exposed to lamivudine [6,9], as lamivudine resistance
reduces the genetic barrier to resistance to entecavir [14]. In
these patients, treatment with TDF is indicated instead. Entecavir
is listed by the US Food and Drug Administration (FDA) as a
pregnancy Category C drug (evidence for teratogenicity in
animals, no trials in humans). TDF is listed as Category B
(no evidence for teratogenicity in animals, no trials in humans)[6].
TDF would thus be preferred in treating pregnant patients.
However, a recent, large randomised trial has found that a
TDF-based antiretroviral therapy administered to HIV-positive
mothers resulted in more deaths of infants within 2 weeks of birth
than a zidovudine-based regimen [15].
Adefovir and lamivudine are less effective than TDF or entecavir,
and associated with higher rates of resistance, and are thus less
recommended as first-line treatments in adults [6,9,10]. In
addition, adefovir shows a significant level of nephrotoxicity
[9,16]. In the UK, NICE guidelines do not recommend the use of
adefovir in the treatment of CHB in adults [12]. Emtricitabine has
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Abstract
Background: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass
treatment programmes for hepatitis B will require very low drug costs. International treatment guidelines recommend
first-line monotherapy with either entecavir or tenofovir disoproxil fumarate (TDF). While the basic patent on TDF expires
in 2017/8, entecavir is already generic in several countries, including the US. The chemical structure of entecavir is related
to abacavir, which costs <$200 per person-year in low-income countries.
Methods: The clinical efficacy, chemical structures, daily doses, routes of chemical synthesis, costs of raw materials and
patent expiry dates were analysed for entecavir and TDF. Costs of sustainable, generic production were calculated for
entecavir, and compared with published originator and generic prices in high- and low-income countries.
Results: With a daily dose of 0.5 mg, one year’s supply of entecavir treatment requires <0.2 g of active pharmaceutical
ingredient (API) per person, estimated to cost $4/year, based on quotations of API production from generic suppliers.
With an additional $20 per year for formulation/packaging and a 50% profit margin, entecavir was estimated to cost a
minimum of $36/person-year, substantially lower than current originator and generic prices. Entecavir is no longer under
patent protection in the USA, China, Brazil and South Africa, with European expiry in 2017. Given differences in daily
dosing, production volumes for entecavir would be 600 times lower than TDF (300 mg once daily) for treating the same
numbers of patients.
Conclusions: Mass treatment for hepatitis B with generic entecavir could be achieved at very low cost in all countries,
provided that important projections can be met in terms of pricing for the API and finished dosage form.
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efficacy against HBV, but has a similar resistance profile to
lamivudine, and is not recommended as monotherapy for CHB
[6,9,10,12]. Pegylated interferon alpha-2b is not approved for
CHB treatment in the US [9], most European countries [6] or
most Asian countries [10].
In HBV/HIV coinfection, treating both infections concurrently is
recommended [6]. A combination of TDF with one of
emtricitabine, lamivudine or other antiretrovirals is recommended
as treatment against both infections [6,9]. Entecavir can be used
as an alternative to suppress HBV if antiretrovirals are provided
separately [17]. However, entecavir without suppressive
alternative nucleoside analogues may lead to nucleoside
mutations in HIV [18], as may TDF monotherapy. HIV tests are
therefore necessary before initiation of entecavir and/or TDF
treatment.
Treatment of HBV with potent NAs results in a reduction in the
incidence of HCC [19].
Number on treatment
Treatment with recommended NAs is unavailable to the majority
of patients in developing countries, often due to the current high
price of therapy [3,20,21]. Approximately 40% of those
diagnosed with CHB in Europe are not on treatment [22]. In
Greece, it is estimated that only 34% of people diagnosed with
CHB are on treatment [23], in Australia, this figure is 9% [24],
and in the US, it is between 8% and 13% [25]. One study found
that only 18% of those on treatment for CHB in the UK were
receiving the recommended therapies [26].
In countries where health systems in general reach a smaller
proportion of the population, the proportion of those with CHB
receiving treatment may be lower. The proportion receiving the
newest, recommended treatments is likely to be lower still.
Patent status and prices
Table 1 gives an overview of patent status and prices for drugs
used in the treatment of HBV. Entecavir and adefovir are now off
patent in the US, and lamivudine is off patent both in the US and
the European Union (EU). Of the newer NAs, entecavir is the
most expensive both in the US – a developed country with
historically high drug prices – and globally. For all five drugs, a
large difference between originator and generic prices can be
seen, for example $15,111 versus $427 for entecavir and $10,718
versus $38 for tenofovir. The lowest generic price for entecavir
($427) is noticeably higher than those for lamivudine ($10),
emtricitabine ($62) and TDF ($38), a result of the fact that the
other drugs have been in use for longer, have multiple generic
manufacturers, and are used in first-line treatment of HIV and
thus under great demand from international agencies.
A recent study on the minimum target prices of directly acting
antiretrovirals (DAAs) in hepatitis C (HCV) therapy estimated the
potential costs of manufacture for the treatment of millions (i.e.
1–5 million) of patients per year to be hundreds of times lower
than the current retail prices, for example $68–136 for the
manufacture of sofosbuvir, compared with a price of $84,000 in
the US. This highlights the potential for widespread generic
production to enable scale-up of global HCV treatment [27].
Entecavir (Baraclude) was developed by Bristol-Myers Squibb
(BMS), with total sales of more than US$6 billion in the decade
since its launch [28–30]. At an approximate price of
$15,000/patient-year in the US, however, this represents only
400,000 patient-years of treatment. This statement is not to
dispute the logic of originator drug pricing, but it does serve to
highlight the differences in approach between providing patented
drug treatments for high-income populations versus providing
mass treatment of generic drugs for low- and middle-income
countries.
This paper analyses the global prices of entecavir, estimates its
potential cost of manufacture for several million patient-years of
treatment, and proposes mechanisms to expand the treatment
of CHB globally.
Methods
Efficacy of entecavir
Clinical trials were identified in PubMed using the search term
‘entecavir OR baraclude’ and filters ‘Clinical Trial’ and ‘Humans’.
This returned 171 results on 11 January 2015. Studies were
assessed for design type and interventions used. The summary
of product characteristics (SmPC) [31] and package insert for
entecavir [32] were also reviewed.
Calculation of treatment cost
We estimated a reasonable market demand for generic entecavir
to provide incentive for effective competition to reach low
production costs: a mass of 2 tonnes of the active pharmaceutical
ingredient (API) per year was assumed. This figure was
established in iterative discussions with API suppliers as a
‘reasonable figure’ to capture some economies of scale in API
production. For finished pharmaceutical production (FPP), this
represents roughly 4 billion tablets, which would allow for
optimised production pricing. Except in patients with suspected
resistance, the once-daily dose of entecavir is 0.5 mg, which
would require 0.18 g of drug per person per year. Therefore,
2 tonnes of entecavir would be sufficient to treat 11 million
people per year, which is less than 5% of those living with CHB
globally [1]. Current entecavir API producers were identified
online and surveyed by email for pricing quotes at a volume of
2000 kg. Twenty companies were surveyed, representing a mix of
generic producers with or without Stringent Regulatory Authority
(SRA) approvals for entecavir or other drugs. There was no strong
correlation between quoted pricing and SRA approvals.
Companies did offer that SRA-approved material would cost
between 20% and 45% more than non-SRA API.
To calculate a target price for entecavir, we estimated the cost of
the API, excipients, tableting, shipping and packaging. We
calculate the cost of production based on these estimates, and
add a 50% mark-up to give a realistic target price. We use upper
estimates throughout and assume relatively inefficient
manufacture and logistics to provide a conservative estimate of
the cost of entecavir production.
Patent coverage
To analyse entecavir patent coverage, relevant patents were
identified, and relevant legal cases were reviewed. The lowest
prices of entecavir were identified in nine countries, using
published figures for government procurement where possible,
as well as online price comparison tools and personal
communications with global pharmaceutical pricing experts.
Lowest prices for these drugs in the US were gathered from
online price comparison tools. References for entecavir prices in
different countries are provided in Appendix 1.
Prices for generic TDF, lamivudine, adefovir and emtricitabine
were collected from prices published in the World Health
Organization’s Global Price Reporting Mechanism (GPRM) [33]
for SRA-approved products. We also reviewed prices reported by
the Clinton Health Access Initiative (CHAI) [34] and Médecins
Sans Frontières (MSF) [35]. Figures reported by CHAI represent
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maximum ‘ceiling’ prices that manufacturers may charge
governments of countries in the CHAI Procurement
Consortium [34]. Prices in the Médecins Sans Frontières (MSF)
Untangling The Web report originate from surveys sent to the
manufacturers by MSF. GPRM lists prices of medicines derived
from completed purchases reported by agencies such as the
Global Fund, PEPFAR, UNITAID and others. Prices listed as
lowest global prices in Table 1 are prices reported by GPRM, as
these represent ‘real-world’ values, that is minimum prices of
completed transactions in 2014
Results
Efficacy in randomised trials
Entecavir showed significantly higher rates of viral suppression
than lamivudine (3TC) in both HBeAg-positive and
HBeAg-negative patients, in two randomised trials (Table 2).
Only one trial directly comparing entecavir to TDF was found, the
results of which were not statistically significant [36]. Other
studies were identified, but were excluded due to having a
retrospective, non-randomised or open-label study design, or for
not being direct comparator studies. The ClinicalTrials.gov
database lists one ongoing trial in which TDF and entecavir are
directly compared; however, this study is focused on renal
function and is of an open-label, case–control design [37].
The European SmPC and the package insert for TDF cite studies
comparing TDF with adefovir, but do not include direct
comparisons of TDF with either entecavir or lamivudine
monotherapies [38,39].
Chemical structure and cost of manufacture
Entecavir is a guanosine nucleoside analogue. Its full chemical
name is 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-
(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
monohydrate, and its molecular weight is 295.3. The structure of
entecavir is shown in Figure 1. There are three chiral centres in
the structure and entecavir is synthesised as the 1S, 3R, 4S
enantiomer [32]. The chemical structure of entecavir is related
to the nucleoside analogue abacavir, which is sold as an FPP for
under $200/person-year in low-income countries [33–35]. Both
structures contain 5-membered carbocycles substituted with a
hydroxymethyl group in position 3 and a purine analogue
heterocycle. Entecavir is made by a substantially different, and
more expensive, chemical synthesis than traditional nucleosides
and abacavir. However, the dose used is very low (0.5 mg),
providing an opportunity for large-scale treatment at low cost.
A flowchart displaying the calculations and assumptions is given
in Figure 2, and described below. The standard daily dose for
entecavir is 0.5 mg. Thus, the volume of API required is 0.1825
grams per patient-year. At a volume demand of 2 tonnes/year,
generic manufacturers of the API estimated charges of
$11,000–22,000/kg. The API manufacturers interviewed were a
mix of those with and without SRA-approved production; there
was no strong correlation between prices quoted and SRA
approvals. Companies who were specifically questioned offered
that SRA-approved pricing would be about 20–45% higher than
for non-SRA approved API. Pricing at $11,000–22,000/kg
Table 1. Expiry dates for basic patents, and global price overview for HBV drugs
Drug Expiry datesa US lowest priceb Global lowest price (US$ pppy)
USA EU
Entecavir (ETV) 2015 (invalidated 2014) 2017 $15,111** originator $427c
$6,127** generic
Adefovir (ADV) 2014 2016 $13,480** originator $133c
Emtricitabine (FTC) 2021 2016 $6,203** originator $62d*
Tenofovir disoproxil fumarate (TDF) 2018 2018 $10,718** originator $38e***
Lamivudine (3TC) 2010 2010 $2,627** originator $10e*
$1,047** generic
For lamivudine, all prices are reported for doses used in treating HIV, as comparable information is only available for this dose – 150mg. For adefovir, no global
price overview exists, but the lowest price of generic adefovir in India is shown to give an impression
a All patent dates from Gilead 2012 Form 10-K Annual Report [48]; b goodrx.com lowest price of authorized pharmacy, including coupon discount [55]
c drugsupdate.com [56]; d Lowest price as reported by MSF[35]; e Lowest ‘incoterms’ price as reported in the WHO’s Global Price Reporting Mechanism in 2014 [33]
* WHO prequalified; ** USFDA approved; *** WHO prequalified and USFDA approved; pppy: per person per year
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Figure 1. The chemical structures of (a) abacavir and (b) entecavir
Figure 1. (from PubChem)
Table 2. Double-blind randomised controlled trials for entecavir: 48-week results
Trial HBeAg Endpoint Entecavir 0.5 mg OD (%) Lamivudine 100 mg OD (%)
ETV-022 [57] Positive HBV DNA 236/354 (67%) 129/355 (36%)
<300 copies/mL
ETV-027 [58] Negative HBV DNA 293/325 (90%) 225/313 (72%)
<300 copies/mL
P values for all results in table are <0.001. More than 80% of patients in both studies were treatment naïve, with similar proportions in both arms
(a)
(b)
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results in the cost of API being $0.0055–0.011 per tablet at the
standard 0.5 mg dose. We assumed the cost of the API to be the
higher extreme of this range ($22,000/kg).
Typical excipients used in entecavir tablets include povidone,
crospovidone, lactose monohydrate, magnesium stearate and
microcrystalline cellulose [32]. Of these, the most expensive by
far is povidone, which costs $11.70–15.27 per kilogram.
Commercial Baraclude tablets weigh 205 mg and contain
approximately 60% (120.5 mg) lactose monohydrate and 32%
(65 mg) microcrystalline cellulose [40]. The typical tablet is likely
to contain a maximum of 15% povidone as a solubility enhancing
agent [41]. We have used cost figures for the prices of excipients
to estimate a reasonable maximum excipient cost of $0.0008 per
tablet. The combined cost of API and excipient comes to $0.012
per tablet.
We assume the cost of tableting (combining ingredients, pressing
pills and quality control) to be about $0.04 per tablet. Thus, our
conservative estimate of the price of API, excipient, coating and
tableting is $0.052 per tablet. For comparison, generic placebo
tablets, which contain all the excipients of an active tablet, are
generally listed at values between $0.01 and $0.05. A personal
interview with the Director of generic product development at a
large pharmaceutical company suggests that typical tablet
production costs (including excipients) are between $0.01 and
$0.03/tablet; informal feedback from Supply Chain Management
Systems (Arlington, VA) is that tablets typically cost about $0.03
to manufacture for the PEPFAR programme. These costs include
the price of excipients but not of API.
The larger component of the cost of treatment with entecavir is
primary and secondary packaging and distribution. We assume a
full (primary and secondary) packaging cost of $1.00/bottle, with
30 dosage units (1 month’s supply) in each bottle. Allowing $0.33
for packaging and distribution per bottle, our final estimate for
the cost of delivering generic entecavir treatment is $2/month,
or $24/person-year. Adding a 50% profit margin gives a target
price of $36/person-year.
The cost of the active pharmaceutical ingredient is about
$2–4/year. We used the higher estimate for API cost, and at $4
this represents 11% of our target price. Packaging, shipping and
mark-up represent 48% of our target price.
The current lowest price for TDF API is $220 per kilogram [42].
The amount of API needed ($0.066 for a 300 mg dose) therefore
costs six times more than the API needed for entecavir ($0.011
for a 0.5 mg dose).
Patent expiry
Table 3 shows patent numbers and expiry dates in selected
countries. The basic patents on entecavir were filed in 1990 and
1991. The basic patent for entecavir in the US was invalidated in
2014 (Appendix 2). In China and Brazil, the basic patents expired
in 2011 (Appendix 2). In Europe, having received a
Supplementary Protection Certificate of 5 years, and a 6-month
extension for paediatric indication, patents on entecavir will
expire in 2017. In some cases, confirmation of these extensions
is pending (Appendix 2). In all these countries, there are a number
of formulation patents in force.
A number of generics companies produce entecavir. TEVA sells
generic entecavir in the US [43]. Cipla, Zydus and Ranbaxy
manufacture versions in India [44]. TEVA is SRA-approved while
Cipla, Zydus, and Ranbaxy have applied for SRA approvals.
Several manufacturers produce generic entecavir in
China [45,46]. While the basic patent for entecavir has lapsed in
South Africa, Doctors Without Borders has reported that generic
entecavir is not being produced or imported due to fears that the
originator company will rapidly take out 'evergreening' patents,
benefiting from South Africa's system of granting patents [47].
It is unclear whether generic competition exists in Brazil. All
entecavir bought by the Ministry of Health in Brazil has been
supplied by a subsidiary of Bristol-Myers Squibb (Appendix 1).
Patent protection for TDF expires in 2018 in the US and the
EU [48] (Table 1). Many key patent applications for tenofovir (in
its various forms) have been rejected by the Indian patent office,
and generic production began there in 2005 [49]. While some
patent applications are still pending in India, Gilead Sciences
signed a voluntary license (VL) agreement with the Medicines
Patent Pool in 2006, allowing generic production of TDF by
Indian companies irrespective of patent applications for the
treatment of HIV and HBV [49,50]. However, this licence is
limited to Indian generic manufacturers, and disallows export to
many middle-income countries with large HIV and HBV
Table 3. Expiry dates of basic patents on entecavir in selected
countries
Country Number Expiry date Status
US US5206244 21 February 2015* Invalidated
UK EP0481754 15 April 2017*† Extension
in force
France EP0481754 1 April 2017* Extension
in force
Germany EP0481754 16 April 2017*† Extension
in force
India 213457 2 July 2022‡ Unclear
China CN1030916 20 November 2011 Expired
Brazil PP 1100846-6 B1 18 October 2010 Expired
South Africa 1991/07894 2011‡ Expired
References for patents and term extensions can be found in Appendix 2
* Expiry date of extended patent term
† Date shown assumes granting of 6-month paediatric extensions,
requests for which have been filed with the European Patent Office
‡ Expiry date estimated as 20 years after filing
Entecavir standard dose
0.5 mg/day
Amount of API needed
0.1825g/year
API estimated cost (maximum)
US$22,000/kg
API cost per tablet
US$0.011
Add cost of formulation (excipients & coating)
at US$0.0008 per tablet
= US$0.012
Add cost of tableting at US$0.04 per tablet
= US$0.052
One month’s supply
= US$1.55
Allow US$0.35 for bottling, package insert, shipping
= US$2.00/month
Cost of delivering generic entecavir per person-year
= US$24.00
Add 50% mark up to give target price
= US$36.00/person per year
Figure 2. Assumptions and calculation of generic entecavir target price
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epidemics, such as China, Brazil, Russia, Egypt and Ukraine [50].
Despite a disputed patent application on TDF in Brazil, the
government has announced that generic TDF will be produced
locally [49]. Following negotiations for discounts, one of the
patents for TDF was revoked in China in 2013 [51].
Basic patent protection for lamivudine expired in 2010 in the US,
Europe [48] and China [35], and WHO-prequalified or
SRA-approved lamivudine is available at very low cost from
Indian generic producers (Table 1) [35]. GlaxoSmithKline held an
additional patent for use in CHB treatment, which expired in
2014 in the US [52] and 2012 in the EU [53].
Current prices
As shown in Figure 3, entecavir is bought at a wide range of prices
worldwide, with the generic version in India sold for less than 3%
of the price of the originator drug in the US, and less than 7% of
the price of the generic sold in US pharmacies (NB the generic
versions of entecavir sold in India are not approved by SRA, nor
are they WHO-prequalified, although their manufacturers have
been approved nationally according to WHO Good
Manufacturing Practice guidelines). In the UK, France and Spain,
where the drug is under patent until early 2017, prices are similar
at around US$7,000/patient per year – slightly less than half the
price in the US. The prices of the originator drug offered to India,
Russia and Brazil are similar. The price of generic entecavir in
China is similar to the prices of the originator drug in India, Russia
and Brazil.
The lowest prices for originator and generic TDF and lamivudine,
in the US and globally, are far lower than the cheapest prices for
entecavir. Originator TDF costs $10,718 in the United States –
roughly two-thirds of the price of originator entecavir (Table 1).
The lowest global price for a completed sale of generic,
SRA-approved TDF is $38 per person-year. In the US, originator
lamivudine costs $2,627 while generic lamivudine is $1,047;
however, the global cheapest is $10/person-year (WHO
prequalified). The global lowest prices of TDF and lamivudine are
also significantly lower than previous independent estimates for
lowest price based on analysis of production costs [27]. These
prices, however, have in many cases been negotiated for the
procurement of the drug for only HIV treatment.
Discussion
Hepatitis B infection leads to approximately 686,000 deaths per
year. This life-threatening viral infection could be controlled
using entecavir treatment costing $36/person-year. This
conservatively estimated target price of $36 is far below the
$15,111 that is charged for the originator version in the US and
the more than $6,000 charged for originator versions in Europe
and Teva’s generic version in the US.
At this price, entecavir would be the cheapest recommended
first-line monotherapy for treating chronic hepatitis B, achieving
prices below those of TDF. Entecavir priced at $36/patient-year
could allow expansion of chronic hepatitis B treatment in low-
and middle-income countries, avoiding significant numbers of
cases of cirrhosis and/or primary liver cancer, and yielding
massive savings in high-income countries.
We have estimated the target price conservatively, including a
generous 50% profit margin on top of total production and
shipping costs. Generic production at this price would thus be
highly sustainable, and attract competitors. While 2 tonnes/year
of entecavir does not sound like a large volume, it is clear from
our discussions with API suppliers that there will be fierce
competition in such a market. The reason for this is simple:
2 tonnes of entecavir at $22,000/kg represents US$44 million in
annual API sales. By comparison, at an API price of approximately
$220/kg, API producers would have to sell 200 tonnes of TDF
API in order to achieve the same revenue. At $22,000/kg the
margin per kg on entecavir API sales will also be vastly larger
than for TDF. There is the potential for entecavir to be priced
below $36/person-year, if lower profit margins were accepted by
generic companies.
If sold at or near the target price, entecavir would be cheaper than
the cheapest versions of TDF, its therapeutic alternative. The
global minimum price for TDF is reported variously in different
resources. The WHO Global Price Reporting Mechanism (GPRM)
reports a minimum price of TDF of $38 in 2014, and a median (of
transactions with medical aid agencies) of $46 [33]. The CHAI
Antiretroviral ceiling prices list sets a ceiling of $54 for TDF [34].
It is also important to note the differences in logistical
requirements between TDF and entecavir. Because of the large
difference in dose (300 mg for TDF; 0.5 mg for entecavir), for
every tonne of entecavir API produced by a manufacturer, 600
tonnes of TDF API would need to be produced for the same
number of patient-years of treatment. Besides logistical
differences, the active pharmaceutical ingredients used in
entecavir and TDF, at standard doses, differ by a factor of six –
$0.011 per pill for entecavir, and $0.066 for TDF [42]. The
differences in API cost and dosage underline the potential for
competitive production of entecavir achieving lower prices per
patient than TDF.
Current prices for generic entecavir (Figure 3), while far lower
than originator prices, are still significantly higher than our
estimate. The global lowest price of entecavir is
$427/patient-year  from a producer who is not SRA-approved
at this time. In the US, the difference between lowest generic
price and the target price is even more dramatic. This price
disparity between target generic price and observed current
generic prices may be explained by a self-perpetuating cycle
between the high price and usage: high prices lead to entecavir
being used at relatively low volumes, and these low volumes make
demand appear to be low, leading to insufficient generic
competition. At the same time, this may simply reflect a lack in
efforts by buyers (such as national healthcare systems, bulk
purchasers) to negotiate lower prices. These processes are clearly
counterproductive to the recommendations of guidelines for use
of entecavir as a first-line monotherapy for chronic
hepatitis B [6,10].
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Increasing the number of patients treated with entecavir rather
than other drugs is both recommended by guidelines, and will
allow further reduction in price by increasing purchase volumes.
Besides making widespread treatment possible with the
recommended therapies, production of affordable entecavir
would allow a two-pronged approach to eradication of hepatitis
B globally. While vaccine use has been expanded
dramatically [54] with considerable effects in curbing HBV,
treatment for the over 350 million who are chronically infected
could prevent the onward transmission of the virus.
There are significant rates of co-infection with HCV and HIV, and
there is the potential for resistance of one virus to drugs being
used to treat another. Therefore combined testing for HBV, HCV
and HIV should be strongly encouraged to optimise selection of
treatment. 
Lastly, affordable entecavir would provide a second-line
treatment for those patients experiencing the toxicity-associated
side effects of TDF such as nephrotoxicity and effects on bone
density [6,9,13].
The cost of manufacturing entecavir is clearly not linked to
current prices.  The cost of patented medicines in high-income
countries is hypothetically reflective of three considerations: (1)
the inherent value of treatment; (2) consideration granted for
the investment in bringing a new product(s) to the market; and
(3) incentive to reward innovation. With this paper, we are not
entering into a discussion of what entecavir or other treatments
under patent should cost in high-income countries. However,
many people, even in high-income countries, do not receive the
current standard of treatment, or in fact, any treatment at all for
hepatitis B. The Global Fund, UNICEF, PEPFAR and other NGOs
target making medicines accessible to patients in low- to middle-
income countries. As NGOs consider the opportunity to scale up
treatment of hepatitis B in low- to middle-income countries, it is
of value to the broader community to understand the potential
minimum cost of large-scale treatment for CHB using standard-
of-care treatments.
We are estimating the potential cost for accessing treatment for
several million patients per year from generic suppliers in a
competitive market. This is a much larger scale of treatment than
currently exists worldwide. It is highly unlikely that the originator's
cost of manufacturing entecavir even approaches our estimated
potential cost of treatment, given that the number of patients on
treatment and volume demand is much lower than for our
estimates.  We do, however, believe that our analysis suggests that
large-scale treatment can potentially be accessed for considerably
less than the lowest current pricing for generic access.
In conclusion, encouraging widespread competitive generic
production of entecavir would allow dramatic price reductions
and rapid scale-up of HBV treatment globally, with a
well-tolerated regimen that has a high barrier to resistance.
Acknowledgements
Source of funding
This project was not funded.
Conflicts of interest
DG and JF and report no conflicts of interest. AH has received
consultancy payments from Janssen, not connected with this
project. GC has received consultancy payments and funding for
clinical trials from pharmaceutical companies not connected with
this project. SB has received consultancy payment and research
funding from BMS and Gilead not connected with this project.
Authors’ contributions
AH designed the project. AH and GC supervised the study team.
DG conducted the systematic review of treatments and additional
searches. JF analysed the costs of production of the treatments.
All authors critically reviewed the manuscript.
References
1. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet 2014; 384:
2053–2063.
2. World Health Organization. Hepatitis. Available at: www.who.int/csr/
disease/hepatitis/en/ (accessed March 2015).
3. World Health Organization. Hepatitis B: fact sheet number 204. Available at
www.who.int/mediacentre/factsheets/fs204/en/ (accessed March 2015).
4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and
national age-sex specific all-cause and cause-specific mortality for 240 causes of
death, 1990–2013: a systematic analysis for the Global Burden of Disease Study
2013. Lancet 2014; 385: 117–171.
5. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative
chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat
2002; 9: 52–61.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines:
Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185. 
7. Chu C-J, Lee S-D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology,
clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008;
23: 512–520.
8. Kourtis A, Bulterys M. HIV-HBV coinfection: a global challenge. N Engl J Med 2012;
366: 1749–1752.
9. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:
661–662.
10. Liaw Y-F, Kao J-H, Piratvisuth T et al. Asian-Pacific consensus statement on the
management of chronic hepatitis B: a 2012 update. Hepatology Int 2012; 6:
531–561.
11. World Health Organization. Guidelines for the prevention, care and treatment of
persons with chronic hepatitis B infection. WHO, Geneva; 2015. Available at:
http://who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/ (accessed
March 2015).
12. National Institute for Health and Care Excellence. Antiviral treatment in adults with
chronic hepatitis B. NICE; 2014. Available at: http://pathways.nice.org.uk/
pathways/hepatitis-b-chronic/antiviral-treatment-in-adults-with-chronic-
hepatitis-b#path=view%3A/pathways/hepatitis-b-chronic/antiviral-treatment-for-
chronic-hepatitis-b.xml&content=view-index (accessed March 2015).
13. Gill US, Zissimopoulos A, Al-shamma S et al. Assessment of bone mineral density
in tenofovir-treated patients with chronic hepatitis B: can the fracture risk
assessment tool identify those at greatest risk? J Infect Dis 2015; 211: 374–382.
14. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus
resistance to entecavir in nucleoside-naive patients is rare through 5 years-of
therapy. Hepatology 2009; 49: 1503–1514.
15. NIH press release. NIH-sponsored study identifies superior drug regimen for
preventing mother-to-child HIV transmission. November 2014. Available at:
www.nih.gov/news/health/nov2014/niaid-17.htm (accessed March 2015). 
16. Ha NB, Ha NB, Garcia RT et al. Renal dysfunction in chronic hepatitis B patients
treated with adefovir dipivoxil. Hepatology 2009; 50: 727–734.
17. Günthard HF, Aberg JA, Eron JJ et al. Antiretroviral treatment of adult HIV
Infection: 2014 recommendations of the International Antiviral Society-USA panel.
JAMA 2014; 312: 410–425.
18. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir: effects on HIV-
1 replication and resistance. N Engl J Med 2007; 356: 2614–2621.
19. Papatheodoridis G V, Chan HL-Y, Hansen BE et al. Risk of hepatocellular carcinoma
in chronic hepatitis B: assessment and modification with current antiviral therapy.
J Hepatol 2015; 62: 956–967.
20. Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World
J Hepatol 2011; 3: 292–299.
21. Liaw Y-F. Antiviral therapy of chronic hepatitis B: opportunities and challenges in
Asia. J Hepatol 2009; 51: 403–410.
22. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and
treatment for patients with chronic viral hepatitis in Europe: a systematic review.
Liver Int 2014; 34: 1452–1456.
23. Papatheodoridis G, Sypsa V, Kantzanou M et al. Estimating the treatment cascade
of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat 2014;
22: 409–415.
24. Allard N, Maclachlan J, Cowie BC. The cascade of care for Australians living with
chronic hepatitis B: measuring access to diagnosis, management and treatment.
Aust N Z J Public Health 2015: doi: 10.1111/1753-6405.12345.
25. Cohen C, Holmberg SD, McMahon BJ et al. Is chronic hepatitis B being
undertreated in the United States? J Viral Hepat 2011; 18: 377–383.
26. Tedder RS, Rodger AJ, Fries L et al. The diversity and management of chronic
hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis
2013; 56: 951–960.
27. Hill A, Khoo S, Fortunak J et al. Minimum costs for producing hepatitis C direct-
acting antivirals for use in large-scale treatment access programs in developing
countries. Clin Infect Dis 2014; 58: 928–936.
28. Bristol-Myers Squibb Company. Form 10-K: Annual report pursuant to section 13
or 15 (d) of the securities exchange act of 1934. 2007.
Analysis of minimum target prices  109
Journal of Virus Eradication 2015; 1: 103–110 ORIGINAL RESEARCH
29. Bristol-Myers Squibb Company. Form 10-K: Annual report pursuant to section 13
or 15 (d) of the securities exchange act of 1934. 2010. 
30. Bristol-Myers Squibb Company. Form 10-K: Annual report pursuant to section 13
or 15 (d) of the securities exchange act of 1934. 2013.
31. European Medicines Agency. Baraclude (entecavir). Summary of product
characteristics. Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/
medicines/human/medicines/000623/human_med_000670.jsp&mid=WC0b01ac0
58001d124 (accessed March 2015).
32. Bristol-Myers Squibb Company. Full prescribing information: Baraclude (entecavir).
2014. Available at: http://packageinserts.bms.com/pi/pi_baraclude.pdf (accessed
March 2015).
33. World Health Organization. Global Price Reporting Mechanism for HIV, tuberculosis
and malaria. 2014. Available at: www.who.int/hiv/amds/gprm/en/ (accessed
March 2015).
34. Clinton Health Access Initiative. Antiretroviral (ARV) ceiling price list. 2013.
Available at: www.clintonhealthaccess.org/files/CHAI%20ARV%20Ceiling%
20Price%20August%202013.pdf (accessed March 2015).
35. MSF Access campaign. Untangling the web of antiretroviral price reductions, 17th
edition. July 2014. Available at: www.msfaccess.org/sites/default/files/
MSF_UTW_17th_Edition_4_b.pdf (accessed March 2015).
36. Liaw Y-F, Sheen I-S, Lee C-M et al. Tenofovir disoproxil fumarate (TDF),
emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis
B liver disease. Hepatology 2011; 53: 62–72.
37. ClinicalTrials.gov. Search for ‘entecavir AND tenofovir’.
38. eMC. Viread 245 mg film-coated tablets. Summary of Product Characteristics. 2014.
Available at: https://www.medicines.org.uk/emc/history/9008 (accessed March
2015).
39. Gilead Sciences Inc. Full prescribing information: Viread (tenofovir). 2012. Available
at: www.gilead.com/~/media/Files/pdfs/medicines/hiv/viread/viread_pi.pdf
(accessed March 2015).
40. Yousaf AM, Jee J-P, Hwang SR et al. Development of direct compression entecavir
0.5mg-loaded tablet exhibiting enhanced content uniformity. Powder Technol
2014; 267: 302–308.
41. Desai D, Li D, Harianawala A et al. Solubilization of entecavir by povidone to
overcome content uniformity challenges for low-dose tablet formulations.
Pharm Dev Technol 2013; 18: 1305–1313. 
42. Import-Export data showing FOB pricing of shipments from India to manufacturers
in other countries, reviewed by JF. Available at: www.infodriveindia.com (accessed
December 2014)
43. Press release. Teva announces launch of generic Baraclude tablets, 0.5mg and 1mg,
in the United States. Available at: www.tevapharm.com/news/?itemid=%
7BB77E1E3B-2E97-41EA-9519-72CBF420DBC7%7D (accessed March 2015)
44. DrugsUpdate.com. Entavir from Cipla, Entecavir – Baraclude to Entehep. Available
at: www.drugsupdate.com/brand/generic/Entecavir/44641 (accessed March
2015).
45. PRNewswire-Asia. Kun Run Biotechnology Announces That They Have Obtained
the Manufacturing Approval for Entecavir from the China State Food and Drug
Administration. PR Newswire. Haikou, China; 17 June 2010. Available at:
http://www.prnewswire.com/news-releases/kun-run-biotechnology-announces-
that-they-have-obtained-the-manufacturing-approval-for-entecavir-from-the-
china-state-food-and-drug-administration-96550799.html (accessed
March 2015).
46. Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients.
Drug Des Develop 2014; 8: 13–24.
47. Press release. World Hepatitis Day: TAC joins organisations calling for improved
access to HepB vaccines & therapies. Johannesburg, 2014 July. Available at:
www.tac.org.za/news/world-hepatitis-day-tac-joins-organisations-calling-
improved-access-hepb-vaccines-therapies (accessed January 2015).
48. Gilead Sciences Inc. Form 10-K: Annual report pursuant to section 13 or 15 (d) of
the securities exchange act of 1934. 2012.
49. MSF Access campaign. Untangling the web of antiretroviral price reductions, 16th
edition. 2013. Available at: www.msfaccess.org/content/untangling-web-
antiretroviral-price-reductions-16th-edition (accessed March 2015).
50. The Medicines Patent Pool. Licences in the MPP: Gilead Sciences. 2012.
www.medicinespatentpool.org/current-licences/ (accessed January 2015).
51. Palmer E. China revokes patent on Gilead’s Viread. FiercePharma. Available at:
www.fiercepharma.com/story/china-revokes-patent-gileads-viread/2013-08-07
(accessed March 2015).
52. GlaxoSmithKline. Annual report 2013. www.gsk.com/media/325156/annual-
report-2013.pdf (p. 229; accessed March 2015).
53. GlaxoSmithKline. Annual report 2010. www.gsk.com/media/279952/annual-
report-2010.pdf (p. 15; accessed March 2015)
54. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol
Hepatol 2013; 28 Suppl 1: 7–10. 
55. GoodRx [Internet]. 2014 [cited 2014 Dec 30]. Available from: www.goodrx.com/
56. DrugsUpdate.com. Medicine INN name searched on 6 Jan 2015.
57. Chang T, Gish R, de Man R et al. A comparison of entecavir and lamivudine for
HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.
58. Lai C-L, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with
HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.
(Erratum in: N Engl J Med 2006; 354: 1863.)
Appendix 1. References for prices of entecavir in selected
countries
Country Price for 360 pills of Ref number
0.5 mg entecavir (US$)
US (originator) 15110.64 [1]
US (generic in store) 6126.72 [1]
France (originator) 7045.57 AG Hasenknopf,
personal communication
November 2014
UK (originator) 6826.03 [2]
Spain 6762.42 [3]
South Africa 2846.99 [4]
Thailand 2440.77 [5]
India (originator) 1312.49 [6]
India (generic) 426.69 [6]
Russia (government 1302.88 [7]
ceiling price; originator)
China (generic)
Hunan 1421.54 [8]
Shandong 1013.34 [9]
Beijing 1258.56 [10]
Henan 1337.82 [11]
Mean for four provinces: 1257.82
Brazil 1161.13 [12]
Prices in other currencies were converted to US$ using exchange rates
at 19th December 2014.
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Appendix 2. References for patents listed in Table 3
Country Number References
United States US5206244 [1–3] 
United Kingdom EP0481754 [4]
France EP0481754 [4]
Germany EP0481754 [4,5]
India 213457 [6,7]
China CN1030916 [4,8]
Brazil PP 1100846-6 B1 [4,9,10]
South Africa 1991/07894 [11]
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